U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07733466) titled 'Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma' on June 27.
Brief Summary: The goal of this clinical trial is to learn the overall response rate of giving immunothrapy before surgery in treatment-naive, advanced stage patients with Betal-nut-associated oral cavity cancer.
The outcomes to be measured by CT scan are overall response rate of either partial or complete response.
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
Betel-nut-associated Oral Carcinoma
Intervention:
DRUG: Pembrolizumab and cetuximab
neoadjuvant immunotherap...